BIOMAT Database Logo BIOMAT Database Logo

Deficit of T-cell recovery after allogeneic bone marrow transplantation in chronic myeloid leukemia patients. 1995

H R Diamond, and M H Souza, and L F Bouzas, and D G Tabak, and M M Campos, and F P Câmara, and V M Rumjanek
Bone Marrow Transplantation Unit, National Cancer Institute, Rio de Janeiro, Brazil.

The immunological reconstitution that follows bone marrow transplantation (BMT) was studied in 40 leukaemia patients: 19 with chronic myeloid leukaemia (CML), 12 with acute myeloid leukaemia (AML) and the remaining 9 with acute lymphoblastic leukaemia (ALL). The recovery of the CML group was slower than that of the ALL and AML groups. This difference was produced by the T cell compartment, as NK cell activity and B cell numbers did not differ significantly. Factors such as conditioning treatment and graft versus host disease (GVHD) prophylaxis were analysed. Our experience suggests that all leukaemia patients should not be considered as one group when analysing their immunological reconstitution, as factors related to the original disease may affect their outcome.

UI MeSH Term Description Entries
D007694 Killer Cells, Natural Bone marrow-derived lymphocytes that possess cytotoxic properties, classically directed against transformed and virus-infected cells. Unlike T CELLS; and B CELLS; NK CELLS are not antigen specific. The cytotoxicity of natural killer cells is determined by the collective signaling of an array of inhibitory and stimulatory CELL SURFACE RECEPTORS. A subset of T-LYMPHOCYTES referred to as NATURAL KILLER T CELLS shares some of the properties of this cell type. NK Cells,Natural Killer Cells,Cell, NK,Cell, Natural Killer,Cells, NK,Cells, Natural Killer,Killer Cell, Natural,NK Cell,Natural Killer Cell
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D013601 T-Lymphocytes Lymphocytes responsible for cell-mediated immunity. Two types have been identified - cytotoxic (T-LYMPHOCYTES, CYTOTOXIC) and helper T-lymphocytes (T-LYMPHOCYTES, HELPER-INDUCER). They are formed when lymphocytes circulate through the THYMUS GLAND and differentiate to thymocytes. When exposed to an antigen, they divide rapidly and produce large numbers of new T cells sensitized to that antigen. T Cell,T Lymphocyte,T-Cells,Thymus-Dependent Lymphocytes,Cell, T,Cells, T,Lymphocyte, T,Lymphocyte, Thymus-Dependent,Lymphocytes, T,Lymphocytes, Thymus-Dependent,T Cells,T Lymphocytes,T-Cell,T-Lymphocyte,Thymus Dependent Lymphocytes,Thymus-Dependent Lymphocyte

Related Publications

H R Diamond, and M H Souza, and L F Bouzas, and D G Tabak, and M M Campos, and F P Câmara, and V M Rumjanek
Chronic myeloid leukemia: management of relapse after allogeneic bone marrow transplantation.
June 1993, Leukemia & lymphoma,
H R Diamond, and M H Souza, and L F Bouzas, and D G Tabak, and M M Campos, and F P Câmara, and V M Rumjanek
Chronic myeloid leukemia treated by allogeneic bone marrow transplantation.
February 1992, Transplantation proceedings,
H R Diamond, and M H Souza, and L F Bouzas, and D G Tabak, and M M Campos, and F P Câmara, and V M Rumjanek
Outcome for patients who relapse after allogeneic bone marrow transplantation for chronic myeloid leukemia. Chronic Leukemia Working Party. European Bone Marrow Transplantation Group.
November 1993, Blood,
H R Diamond, and M H Souza, and L F Bouzas, and D G Tabak, and M M Campos, and F P Câmara, and V M Rumjanek
Isolated extramedullary relapse after allogeneic bone marrow transplantation for chronic myeloid leukemia.
July 1998, Bone marrow transplantation,
H R Diamond, and M H Souza, and L F Bouzas, and D G Tabak, and M M Campos, and F P Câmara, and V M Rumjanek
Interferon alpha for chronic myeloid leukemia relapsing after allogeneic bone marrow transplantation.
March 1999, Bone marrow transplantation,
H R Diamond, and M H Souza, and L F Bouzas, and D G Tabak, and M M Campos, and F P Câmara, and V M Rumjanek
Molecular analysis of relapse in chronic myeloid leukemia after allogeneic bone marrow transplantation.
September 1987, Blood,
H R Diamond, and M H Souza, and L F Bouzas, and D G Tabak, and M M Campos, and F P Câmara, and V M Rumjanek
Molecular basis for therapeutic decisions in chronic myeloid leukemia patients after allogeneic bone marrow transplantation.
October 2000, Haematologica,
H R Diamond, and M H Souza, and L F Bouzas, and D G Tabak, and M M Campos, and F P Câmara, and V M Rumjanek
[Allogeneic bone marrow transplantation in the treatment of chronic myeloid leukemia].
November 1987, Nederlands tijdschrift voor geneeskunde,
H R Diamond, and M H Souza, and L F Bouzas, and D G Tabak, and M M Campos, and F P Câmara, and V M Rumjanek
Alpha-2b-interferon as single therapy for patients with chronic myeloid leukemia relapsing after T-cell depleted allogeneic bone marrow transplantation.
January 1990, European journal of haematology. Supplementum,
H R Diamond, and M H Souza, and L F Bouzas, and D G Tabak, and M M Campos, and F P Câmara, and V M Rumjanek
Donor leukocyte infusions for chronic myeloid leukemia relapsed after allogeneic bone marrow transplantation.
March 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
Copied contents to your clipboard!